Name: Biomarkers in Critical Care,An Issue of Critical Care Clinics (Volume 36-1) (The Clinics: Internal Medicine, Volume 36-1) (en Inglés)
Price: 278.47 PEN
Availability: InStock
Author: Levy Mitchell
ISBN: 9780323683142

portada Biomarkers in Critical Care,An Issue of Critical Care Clinics (Volume 36-1) (The Clinics: Internal Medicine, Volume 36-1) (en Inglés)

Biomarkers in Critical Care,An Issue of Critical Care Clinics (Volume 36-1) (The Clinics: Internal Medicine, Volume 36-1) (en Inglés)

Formato

Libro Físico

Editorial

Elsevier

Autor

Levy Mitchell

Idioma

Inglés

N° páginas

240

Encuadernación

Tapa Dura

ISBN13

9780323683142

Biomarkers in Critical Care,An Issue of Critical Care Clinics (Volume 36-1) (The Clinics: Internal Medicine, Volume 36-1) (en Inglés)

Levy Mitchell (Autor) · Elsevier · Tapa Dura

Libro Nuevo Importado

Envío: 18 a 23 días háb.

S/ 618,83S/ 278,47

-55%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

S/ 278,47

Llega entre el 16 Jul y el 27 Jul a CERCADO DE LIMA, Lima. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Biomarkers in Critical Care,An Issue of Critical Care Clinics (Volume 36-1) (The Clinics: Internal Medicine, Volume 36-1) (en Inglés)"

This issue of Critical Care Clinics, guest edited by Dr. Mitchell M. Levy, focuses on Biomarkers in Critical Care. This is one of four issues each year selected by the series consulting editor, Dr. John Kellum. Articles in this issue include, but are not limited to: The History of Biomarkers; Biomarkers for Identifying Infection; Procalcitonin: Where Are We Now?; Soluble TREM-1: Diagnosis or Prognosis?; Lubricin as a Biomarker in Sepsis; Check Point Inhibitors and Their Role in Immunosuppression in Sepsis; Metabolomics and the Microbiome as Biomarkers in Sepsis; Lactate: Where Are We Now?; Predicting Renal Dysfunction; Biomarkers in the Evolution of ARDS; Biomarkers and RV Dysfunction; Biomarkers and Precision Medicine: State of the Art; The Use of Biomarkers for Population Homogeneity in Clinical Trials; and The Future of Biomarkers.